Potential mediators of the mortality reduction with zoledronic acid after hip fracture. - Wikidata - awgldk - TriplyDB

Potential mediators of the mortality reduction with zoledronic acid after hip fracture.

Potential mediators of the mortality reduction with zoledronic acid after hip fracture.

http://www.wikidata.org/entity/Q37542295

about

Bisphosphonates can prevent recurrent hip fracture and reduce the mortality in osteoporotic patient with hip fracture: A meta-analysis Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research Fracture prevention in patients with cognitive impairment presenting with a hip fracture: secondary analysis of data from the HORIZON Recurrent Fracture Trial.Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis.Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosis Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club Management of osteoporosis in patients hospitalized for hip fractures Zoledronate Attenuates Accumulation of DNA Damage in Mesenchymal Stem Cells and Protects Their Function.Targeting γδ T cells for immunotherapy of HIV disease If you don't take it - it can't work: the consequences of not being treated or nonadherence to osteoporosis therapy.Timing of the initiation of bisphosphonates after surgery for fracture healing: a systematic review and meta-analysis of randomized controlled trials.Osteoporosis: the emperor has no clothes Cardiovascular diseases in older patients with osteoporotic hip fracture: prevalence, disturbances in mineral and bone metabolism, and bidirectional links Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis.Update on the use of zoledronic acid in the management of osteoporosis.Antiresorptive therapies for osteoporosis: a clinical overview.Current options for the management of postmenopausal osteoporosis.The effect of treatments for osteoporosis on mortality.Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease.Fracture mortality: associations with epidemiology and osteoporosis treatment.Fracture liaison services: promoting enhanced bone health care.The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women.Use of proton pump inhibitors and mortality after hip fracture in a nationwide study.Risk of long-term infection-related death in clinical osteoporotic vertebral fractures: A hospital-based analysis.Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study.The Pharmacological Profile of a Novel Highly Potent Bisphosphonate, OX14 (1-Fluoro-2-(Imidazo-[1,2-α]Pyridin-3-yl)-Ethyl-Bisphosphonate).Positive Effects of a Sufficient Pre-fracture Serum Vitamin D Level on the Long-Term Survival of Hip Fracture Patients in Finland: A Minimum 11-Year Follow-Up.Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study.Mortality rates after incident non-traumatic fractures in older men and women.Heart failure in patients treated with bisphosphonates.Acute phase response after zoledronic acid is associated with long-term effects on white blood cells.Observational studies--just telling us what we want to hear or telling us where we need to look?Bisphosphonates prevent age-related weight loss in Japanese postmenopausal women.Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: A systematic review and meta-analysis.Safety, pharmacokinetics, and changes in bone metabolism associated with zoledronic acid treatment in Japanese patients with primary osteoporosis.Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National Register Based Cohort Study.Monocytes and γδ T cells control the acute-phase response to intravenous zoledronate: insights from a phase IV safety trial.Mortality After Osteoporotic Fractures: What Proportion Is Caused by Fracture and Is Preventable?Once-yearly zoledronic acid in older men compared with women with recent hip fracture.Reduced mortality and subsequent fracture risk associated with oral bisphosphonate recommendation in a fracture liaison service setting: A prospective cohort study.

P2860

Q26749442-39A72A1A-0C44-4EEA-AF24-4E77F86805FF Q26782621-F49C5D34-92A6-4CBE-BE7D-D3F538BE9DDB Q30652322-63E0F148-0236-498F-9337-B9F1D91090A3 Q34018048-1376AAB7-19D9-4A67-AADF-0365A35FCCA6 Q34042003-9707F69D-4E89-4CC1-AB5B-4672FB079804 Q34099162-B38E64C0-7213-494F-9ECF-883B97353999 Q34284002-755061C6-B2DB-4025-A905-1AA9A0817940 Q34505560-A3419580-7FB4-4E92-9157-0749E0101BF0 Q34585223-D8263409-F7C9-4DB9-AAD3-058DC81947F4 Q35050249-06C1653F-6C04-47FA-B334-DB7C83580277 Q35285640-BF03A585-0C7A-475F-AA9E-5B582BAF82C2 Q35835844-0338631F-B0F5-4A28-95F2-9863324D5830 Q36648170-1B3F8534-2378-4AF4-90C8-85AE99C05226 Q37307297-65695D1B-7165-4142-BB60-2F10CFD62380 Q37765866-2330C6D0-8BCE-4C5E-9DC6-F1F58BEB77B8 Q37926914-2C787402-BD12-487F-AA9F-EE80E223385C Q37931985-0693FFFD-7225-47A3-9B0E-7C1751F327A2 Q38053114-9E91E392-8038-4996-9369-ECA1EAC5EC51 Q38104993-1BFD8460-591A-4914-931E-F4D8984A200F Q38236887-A4261CF5-CA98-42C2-A9B3-F69B12D610E4 Q38252846-9CE9F66A-8111-4158-B077-7A3CF037C482 Q38611601-572D67BC-0E28-4993-8535-DA0DC43EA678 Q39023035-6D20D6E7-A646-43E8-8B63-631AA319930E Q40100089-C943879E-5572-441B-8156-D717AD0B04E5 Q40313121-5B90370A-4298-4B72-9DB7-A2BCEFC95986 Q41689098-3BA214D8-826F-46C7-8CF4-8D9A283726F4 Q41757089-9A1F33AF-C029-460A-9A2A-CDEC8731D106 Q43460593-1C639894-0623-43C4-9420-9609772B7FC2 Q44230241-A6BBEAF2-BE45-4559-93FC-AA3BDCCA3D34 Q44389690-16A0568C-3E95-4BE7-9E1F-121BAFF1CC31 Q45731159-B7ADEAA5-CE70-4DB8-AC46-91D4C151F41B Q46105591-240A661B-354C-46A8-943A-A0B3C9B43307 Q47174018-69DE90B4-52CD-4876-A468-2A8C38B1EA9F Q47712068-48EAE70C-E4BD-4C68-BF83-78D23D5462F6 Q47912290-C828F331-9820-4F8F-A780-7A661C4708C8 Q50555866-491F266A-916E-41CD-A381-F718DA5E513C Q50932570-5C9F3604-A5C4-428A-8139-803356BBD099 Q53104294-5DD9AF64-9F25-47AA-BABE-DC43A4208831 Q53141719-728D07D8-AFA5-404D-9A8F-59DF0194C73B Q55170820-2F84FA3F-DE35-4761-B5D4-90D3BECDA840

P2860

Potential mediators of the mortality reduction with zoledronic acid after hip fracture.

http://www.wikidata.org/entity/Q37542295

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Potential mediators of the mortality reduction with zoledronic acid after hip fracture.

@en

Potential mediators of the mortality reduction with zoledronic acid after hip fracture.

@nl

type

label

Potential mediators of the mortality reduction with zoledronic acid after hip fracture.

@en

Potential mediators of the mortality reduction with zoledronic acid after hip fracture.

@nl

prefLabel

Potential mediators of the mortality reduction with zoledronic acid after hip fracture.

@en

Potential mediators of the mortality reduction with zoledronic acid after hip fracture.

@nl

P1433

Q37542295-BFC73507-5370-4F11-AEF1-C9D60990B96A

P1476

Q37542295-097304FA-50E2-4F5A-BA45-C2ECD17B2C81

P2093

Q37542295-02D37DF1-B7FE-4C79-852F-BA7F8F57893F

Q37542295-39C2D359-CBCB-4CA1-BEF1-7FBC68AB401E

Q37542295-46409D1C-960F-48F3-983F-7B6101E72959

Q37542295-5836EA99-3FDF-4715-8296-265609BBE1D8

Q37542295-8ED0BF62-8096-47EC-BD9F-E117727B9E62

Q37542295-96938131-F932-46DB-AD1B-829DD161B1DF

Q37542295-AAB639EF-09DE-4EFD-8473-200A87B45AD2

Q37542295-E916914F-5B29-474B-8DBF-1AF9AC455EDA

P2860

Q37542295-0564B3F1-EDEC-4D18-BB02-FA0143008AC7

Q37542295-0FA4BD63-06AC-4598-B63F-CEB3571C62B6

Q37542295-19DD434F-0C9B-449E-A030-DE2B050BA31C

Q37542295-22745DAD-5855-4273-ACA8-6D4F9A12621E

Q37542295-316FCDB3-79EA-45BA-BBBB-CFC49348BE7B

Q37542295-333EC8AB-4AD4-4E5F-BEEE-171001675CAF

Q37542295-48023F61-7AD8-431A-9103-5A2163FC8FF8

Q37542295-4855FAEE-9ECE-4028-8150-5BEBEEA66791

Q37542295-4E96958D-4C32-4AE7-830F-CED4F2175FB7

Q37542295-54AEB132-2753-4035-B814-3802458540B0

P304

Q37542295-725F6DEE-A8CE-4DDE-9FBB-E4E7ADC655C7

P31

Q37542295-D5454956-EE4B-4AC6-A70B-5E3F5C959BA6

P356

Q37542295-074B55E3-1CAA-4A70-B209-82958C9064D1

P433

Q37542295-2641484B-89D7-4ED6-9D0D-1FB47DE499F1

P478

Q37542295-5B62B260-16A1-40E6-A171-9E96B4A89A31

P577

Q37542295-2AFD8F11-0517-4CF8-83B2-DE14CAAE15B6

P5875

Q37542295-27784594-1BC4-4D58-9CD7-823144FD980F

P698

Q37542295-71993DCC-1BF6-4281-9EC8-C94F7AB3BDFE

P932

Q37542295-470A496C-C5F3-4921-9C4C-FFA7327DB93E

P356

P1433

Journal of Bone and Mineral Research

P1476

Potential mediators of the mortality reduction with zoledronic acid after hip fracture.

@en

P2093

Carl F Pieper

http://www.w3.org/2001/XMLSchema#string

Cathleen S Colón-Emeric

http://www.w3.org/2001/XMLSchema#string

Erik F Eriksen

http://www.w3.org/2001/XMLSchema#string

Jay Magaziner

http://www.w3.org/2001/XMLSchema#string

Kenneth W Lyles

http://www.w3.org/2001/XMLSchema#string

Peter Mesenbrink

http://www.w3.org/2001/XMLSchema#string

Pierre Delmas

http://www.w3.org/2001/XMLSchema#string

Steven Boonen

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of bisphosphonates on prostaglandin E2 and thromboxane B2 production in human whole blood and monocytes stimulated by lipopolysaccharide and A23187

Association between interleukin-6 and lower extremity function after hip fracture--the role of muscle mass and strength.

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Mortality associated with delay in operation after hip fracture: observational study.

Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study.

Zoledronic acid and clinical fractures and mortality after hip fracture.

Excess mortality following hip fracture: the role of underlying health status.

Characterization of oxidized low-density lipoprotein-induced hormesis-like effects in osteoblastic cells.

Interleukin-6 covaries inversely with cognitive performance among middle-aged community volunteers.

Volumetric and areal bone mineral density measures are associated with cardiovascular disease in older men and women: the health, aging, and body composition study.

P304

91-97

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1359/JBMR.090704

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26650330

http://www.w3.org/2001/XMLSchema#string

P698

19580467

http://www.w3.org/2001/XMLSchema#string

P932

5770987

http://www.w3.org/2001/XMLSchema#string